Nishi K, Kondo T, Narabayashi H, Takubo H, Muramoto S, Araki H
Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
J Neurol Sci. 1989 Aug;92(1):65-70. doi: 10.1016/0022-510x(89)90175-5.
In this study, concentrations of homovanillic acid (HVA), a principal metabolite of dopamine (DA), in the cerebrospinal fluid (CSF) were measured in 17 patients with Parkinson's disease (PD) who had been effectively treated with L-DOPA and in 8 patients clinically diagnosed as having striatonigral degeneration (SND) and for whom treatment with L-DOPA had proved ineffective. L-DOPA administration, consisting of a daily dosage of 600 mg plus 150 mg aromatic L-amino acid decarboxylase inhibitor was continued in all cases for at least 3 months. In the PD group, the HVA value was 511.6 +/- 196.5 pmol/ml and in the SND group, 144.9 +/- 83.4 pmol/ml. This remarkably low value for the SND group suggests that there may exist severe disorders in the uptake and decarboxylation of exogenous L-DOPA.
在本研究中，对17例接受左旋多巴有效治疗的帕金森病（PD）患者以及8例临床诊断为纹状体黑质变性（SND）且左旋多巴治疗无效的患者的脑脊液（CSF）中多巴胺（DA）的主要代谢产物高香草酸（HVA）浓度进行了测定。所有病例均持续给予每日剂量为600 mg加150 mg芳香族L - 氨基酸脱羧酶抑制剂的左旋多巴治疗至少3个月。PD组的HVA值为511.6±196.5 pmol/ml，SND组为144.9±83.4 pmol/ml。SND组这一显著较低的值表明，外源性左旋多巴的摄取和脱羧可能存在严重障碍。
